PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19946310-4	2009	Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS).	paricalcitol	0-12	renin	Homo sapiens	23-28	
23926179-3	2013	We hypothesized that calcitriol and paricalcitol would increase plasma renin activity (PRA) independently of plasma Ca(2+) via hypercalciuria-mediated polyuria, hypovolemia, and subsequent increased beta-adrenergic sympathetic activity.	paricalcitol	36-48	renin	Homo sapiens	71-76	
23167771-0	2012	Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.	paricalcitol	33-45	renin	Homo sapiens	100-105	
22169009-9	2012	In cultured podocytes, paricalcitol and calcitriol at concentrations in the physiological and clinically significant range prevented the increase in MCP-1, IL-6, renin, and fibronectin mRNA expression and the secretion of MCP-1 to the culture media induced by high glucose.	paricalcitol	23-35	renin	Homo sapiens	162-167	
21561543-3	2011	Paricalcitol appears also to block the renin-angiotensin-aldosterone system.	paricalcitol	0-12	renin	Homo sapiens	39-44	
19946310-4	2009	Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS).	paricalcitol	0-12	renin	Homo sapiens	93-98	
19946310-4	2009	Paricalcitol inhibited renin transcription, countering the compensatory ACEI-induced rise in renin, thus achieving a more complete blockade of the renin-angiotensin system (RAS).	paricalcitol	0-12	renin	Homo sapiens	93-98	
33416889-5	2021	Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the renin-angiotensin-aldosterone system through renal changes in renin, ATR1 and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leukocytes (CD45), ADAM17 mRNA, TGF-beta mRNA and protein and maintaining E-cadherin mRNA levels.	paricalcitol	0-12	renin	Homo sapiens	116-121	
33416889-5	2021	Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the renin-angiotensin-aldosterone system through renal changes in renin, ATR1 and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leukocytes (CD45), ADAM17 mRNA, TGF-beta mRNA and protein and maintaining E-cadherin mRNA levels.	paricalcitol	0-12	renin	Homo sapiens	178-183	
33416889-7	2021	CONCLUSIONS: Paricalcitol effectively attenuated the renal interstitial fibrosis induced by CRF through a combination of inhibitory actions on the renin-angiotensin-aldosterone system, inflammation and epithelial/mesenchymal transition.	paricalcitol	13-25	renin	Homo sapiens	147-152	
29715294-0	2018	Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.	paricalcitol	47-59	renin	Homo sapiens	159-164